Skip to main content
. 2020 Jul 19;117(5):1339–1357. doi: 10.1093/cvr/cvaa219

Figure 7.

Figure 7

miR-21-5p and miR-100-5p response during senescence and in coronary artery disease patients. (A) miRNA expression in passage (p) 8–16 cells compared to p4 cells. (B) miRNA levels in growth medium of p8–p16 cells compared to p4 cells. (C) miRNA levels in exosomes extracted from the growth medium of p8–p16 cells compared to p4 cells. (D) As in (A) but under oxPAPC stimuli. (E) As in (B) but under oxPAPC stimuli. (F) As in (C) but under oxPAPC stimuli. For (A–F) figures: n = 3, mean ± SD, unpaired two-tailed t-test, ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05. (G) miR-21-5p and miR-100-5p levels in human pericardial fluid of coronary artery disease (CAD) patients (n = 22, mean ± SD). (H) miRNA levels in pericardial fluid exosomes of control and CAD groups (n = 16 for control, n = 22 for CAD, mean ± SD, unpaired two-tailed t-test, *P < 0.05). (I) miRNA levels in pericardial fluid exosomes of CAD patients divided according to the severity of heart failure symptoms (NYHA classes I–IV), where I is no symptoms and IV severe symptoms (n = 4–6 for NYHA II, n = 5 for NYHA III and n = 6–8 for NYHA IV, mean ± SD).